In an interview to CNBC-TV18, Nithya Balasubramanian, Director of Sanford Bernstein spoke at length about pharmaceutical space.

“We have an outperform rating on Cipla, Sun Pharma, Dr Reddy’s Lab and Lupin and among the four Cipla followed by Sun are our top picks,” said Balasubramanian.

Talking about Biocon, she said, “One thing in our mind which can be an important catalyst for Biocon is the interchangeability status on insulin glargine. They have a file pending at the FDA (United States Food and Drug Administration) right now and we do believe that getting interchangeable status for insulin glargine can help them grab meaningful market share in the US.”

For more details, watch the video

(Edited by : Yashi Gupta)